MAP BioPharma’s report Access to Orphan Medicines: A Case for Change was reference at last week’s APPG for Life Sciences meeting.
The All-Party Parliamentary Group (APPG) for Life Sciences meeting, titled ‘Understanding the value of new medicines and diagnostics in the NHS’, included contributions on:
- the Voluntary Pricing and Access Scheme (VPAS) – Paul Catchpole, ABPI
- NICE perspectives on VPAS and access to medicines – Sarah Byron, NICE
- diagnostics and uptake – Darren Stenlake, BIVDA
- rare diseases and access to medicines – Charlotte Galvin, Amicus Therapeutics
MAP’s report was referenced in suggesting that the uptake of rare medicines is inefficient.
Find out more from Access to Orphan Medicines: A Case for Change here.